Cerecidins, novel lantibiotics from bacillus cereus with potent antimicrobial activity

Applied and Environmental Microbiology

Volumn 80, Issue 8, 2014, Pages 2633-2643

  Wang, Jian ^a,b   Zhang, Li ^a,b   Teng, Kunling ^a   Sun, Shutao ^a   Sun, Zhizeng ^c   Zhong, Jin ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BACILLUS CEREUS; BACTERIOLOGY; ENZYME INHIBITION; ESCHERICHIA COLI; GENES;

ANTI-MICROBIAL ACTIVITY; ANTIMICROBIAL PEPTIDE; GRAM-POSITIVE BACTERIUM; QUORUM-SENSING; SERINE PROTEASE; STAPHYLOCOCCUS AUREUS; TRUNCATED VERSIONS; VANCOMYCIN-RESISTANT ENTEROCOCCI;

TRANSCRIPTION;

ANTIMICROBIAL ACTIVITY; DRUG RESISTANCE; ENZYME ACTIVITY; ETHER; GENE EXPRESSION; GENOME; MICROBIAL ACTIVITY; MUTATION; PEPTIDE; SPECIES DIVERSITY;

ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIOCIN;

AMINO ACID SEQUENCE; BACILLUS CEREUS; BIOSYNTHESIS; CHEMISTRY; DNA SEQUENCE; DRUG EFFECTS; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; GRAM POSITIVE BACTERIUM; IC50; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR CLONING; MOLECULAR GENETICS; MULTIGENE FAMILY; POLYMERASE CHAIN REACTION;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACILLUS CEREUS; BACTERIOCINS; BIOSYNTHETIC PATHWAYS; CLONING, MOLECULAR; DNA, BACTERIAL; ESCHERICHIA COLI; GENE EXPRESSION; GRAM-POSITIVE BACTERIA; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84896920111     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.03751-13     Document Type: Article

References (53)

1. Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, Bulaj G, Camarero JA, Campopiano DJ, Challis GL, Clardy J, Cotter PD, Craik DJ, Dawson M, Dittmann E, Donadio S, Dorrestein PC, Entian KD, Fischbach MA, Garavelli JS, Goransson U, Gruber CW, Haft DH, Hemscheidt TK, Hertweck C, Hill C, Horswill AR, Jaspars M, Kelly WL, Klinman JP, Kuipers OP, Link AJ, Liu W, Marahiel MA, Mitchell DA, Moll GN, Moore BS, Muller R, Nair SK, Nes IF, Norris GE, Olivera BM, Onaka H, Patchett ML, Piel J, Reaney MJ, Rebuffat S, Ross RP, Sahl HG, Schmidt EW, Selsted ME, Severinov K, Shen B, Sivonen K, Smith L, Stein T, Sussmuth RD, Tagg JR, Tang GL, Truman AW, Vederas JC, Walsh CT, Walton JD, Wenzel SC, Willey JM, van der Donk WA. 2013. Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat. Prod. Rep. 30:108-160. http://dx.doi.org/10.1039/c2np20085f.
2. Zhang X, Ni W, van der Donk WA. 2005. Synthesis of nonproteinogenic amino acids to probe lantibiotic biosynthesis. J. Org. Chem. 70:6685-6692. http://dx.doi.org/10.1021/jo051182o.
3. Chatterjee C, Paul M, Xie L, van der Donk WA. 2005. Biosynthesis and mode of action of lantibiotics. Chem. Rev. 105:633-684. http://dx.doi.org/10.1021/cr030105v.
4. Paulsen I, Banerjei L, Myers G, Nelson K, Seshadri R, Read T, Fouts D, Eisen J, Gill S, Heidelberg J. 2003. Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science 299:2071-2074. http://dx.doi.org/10.1126/science.1080613.
5. Rice LB. 1998. Tn916 family conjugative transposons and dissemination of antimicrobial resistance determinants. Antimicrob. Agents Chemother. 42:1871-1877.
6. van Heel AJ, Montalban-Lopez M, Kuipers OP. 2011. Evaluating the feasibility of lantibiotics as an alternative therapy against bacterial infections in humans. Expert Opin. Drug Metab. Toxicol. 7:675-680. http://dx.doi.org/10.1517/17425255.2011.573478.
7. Hancock RE, Sahl H-G. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557. http://dx.doi.org/10.1038/nbt1267.
8. Hsu S-TD, Breukink E, Tischenko E, Lutters MA, de Kruijff B, Kaptein R, Bonvin AM, van Nuland NA. 2004. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat. Struct. Mol. Biol. 11:963-967. http://dx.doi.org/10.1038/nsmb830.
9. Ruhr E, Sahl H-G. 1985. Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles. Antimicrob. Agents Chemother. 27:841-845. http://dx.doi.org/10.1128/AAC.27.5.841.
10. Ghobrial OG, Derendorf H, Hillman JD. 2009. Pharmacodynamic activity of the lantibiotic MU1140. Int. J. Antimicrob. Agents 33:70-74. http://dx.doi.org/10.1016/j.ijantimicag.2008.07.028.
11. Piper C, Casey PG, Hill C, Cotter PD, Ross RP. 2012. The lantibiotic lacticin 3147 prevents systemic spread of Staphylococcus aureus in a murine infection model. Int. J. Microbiol. http://dx.doi.org/10.1155/2012/806230.
12. Jabes D, Brunati C, Candiani G, Riva S, Romano G, Donadio S. 2011. Efficacy of the new lantibiotic NAI-107 in experimental infections induced by MDR Gram-positive pathogens. Antimicrob. Agents Chemother. 55:1671-1676. http://dx.doi.org/10.1128/AAC.01288-10.
13. Crowther GS, Baines SD, Todhunter SL, Freeman J, Chilton CH, Wilcox MH. 2013. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J. Antimicrob. Chemother. 68:168-176. http://dx.doi.org/10.1093/jac/dks359.
14. Oliynyk I, Varelogianni G, Roomans GM, Johannesson M. 2010. Effect of duramycin on chloride transport and intracellular calcium concentration in cystic fibrosis and non-cystic fibrosis epithelia. APMIS 118:982-990. http://dx.doi.org/10.1111/j.1600-0463.2010.02680.x.
15. Grasemann H, Stehling F, Brunar H, Widmann R, Laliberte TW, Molina L, Doring G, Ratjen F. 2007. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 131:1461-1466. http://dx.doi.org/10.1378/chest.06-2085.
16. Banerjee S, Hansen JN. 1988. Structure and expression of a gene encoding the precursor of subtilin, a small protein antibiotic. J. Biol. Chem. 263:9508-9514.
17. Stein T, Borchert S, Conrad B, Feesche J, Hofemeister B, Hofemeister J, Entian K-D. 2002. Two different lantibiotic-like peptides originate from the ericin gene cluster of Bacillus subtilis A1/3. J. Bacteriol. 184:1703-1711. http://dx.doi.org/10.1128/JB.184.6.1703-1711.2002.
18. Fuchs SW, Jaskolla TW, Bochmann S, Kotter P, Wichelhaus T, Karas M, Stein T, Entian KD. 2011. Entianin, a novel subtilin-like lantibiotic from Bacillus subtilis subsp. spizizenii DSM 15029T with high antimicrobial activity. Appl. Environ. Microbiol. 77:1698-1707. http://dx.doi.org/10.1128/AEM.01962-10.
19. Phelan RW, Barret M, Cotter PD, O'Connor PM, Chen R, Morrissey JP, Dobson AD, O'Gara F, Barbosa TM. 2013. Subtilomycin: a new lantibiotic from Bacillus subtilis strain MMA7 isolated from the marine sponge Haliclona simulans. Mar. Drugs 11:1878-1898. http://dx.doi.org/10.3390/md11061878.
20. McClerren AL, Cooper LE, Quan C, Thomas PM, Kelleher NL, van der Donk WA. 2006. Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic. Proc. Natl. Acad. Sci. U. S. A. 103:17243-17248. http://dx.doi.org/10.1073/pnas.0606088103.
21. Dischinger J, Josten M, Szekat C, Sahl H-G, Bierbaum G. 2009. Production of the novel two-peptide lantibiotic lichenicidin by Bacillus licheniformis DSM 13. PLoS One 4:e6788. http://dx.doi.org/10.1371/journal.pone.0006788.
22. Altena K, Guder A, Cramer C, Bierbaum G. 2000. Biosynthesis of the lantibiotic mersacidin: organization of a type B lantibiotic gene cluster. Appl. Environ. Microbiol. 66:2565-2571. http://dx.doi.org/10.1128/AEM.66.6.2565-2571.2000.
23. Arguelles-Arias A, Ongena M, Devreese B, Terrak M, Joris B, Fickers P. 2013. Characterization of amylolysin, a novel lantibiotic from Bacillus amyloliquefaciens GA1. PLoS One 8:e83037. http://dx.doi.org/10.1371/journal.pone.0083037.
24. Garg N, Tang W, Goto Y, Nair SK, van der Donk WA. 2012. Lantibiotics from Geobacillus thermodenitrificans. Proc. Natl. Acad. Sci. U. S. A. 109: 5241-5246. http://dx.doi.org/10.1073/pnas.1116815109.
25. Ehling-Schulz M, Fricker M, Scherer S. 2004. Bacillus cereus, the causative agent of an emetic type of food-borne illness. Mol. Nutr. Food Res. 48:479-487. http://dx.doi.org/10.1002/mnfr.200400055.
26. Liao R, Duan L, Lei C, Pan H, Ding Y, Zhang Q, Chen D, Shen B, Yu Y, Liu W. 2009. Thiopeptide biosynthesis featuring ribosomally synthesized precursor peptides and conserved posttranslational modifications. Chem. Biol. 16:141-147. http://dx.doi.org/10.1016/j.chembiol.2009.01.007.
27. Bizani D, Motta AS, Morrissy JA, Terra R, Souto AA, Brandelli A. 2010. Antibacterial activity of cerein 8A, a bacteriocin-like peptide produced by Bacillus cereus. Int. Microbiol. 8:125-131.
28. Ju X-R, Gao Y-L, Yao M-L, Qian Y. 2008. Response of Bacillus cereus spores to high hydrostatic pressure and moderate heat. LWT Food Sci. Technol. 41:2104-2112. http://dx.doi.org/10.1016/j.lwt.2007.11.011.
29. Wu S, Feng C, Zhong J, Huan L. 2007. Roles of S3 site residues of nattokinase on its activity and substrate specificity. J. Biochem. 142:357-364. http://dx.doi.org/10.1093/jb/mvm142.
30. Chiu J, March PE, Lee R, Tillett D. 2004. Site-directed, ligaseindependent mutagenesis (SLIM): a single-tube methodology approaching 100% efficiency in 4 h. Nucleic Acids Res. 32:e174. http://dx.doi.org/10.1093/nar/gnh172.
31. Oman TJ, van der Donk WA. 2009. Insights into the mode of action of the two-peptide lantibiotic haloduracin. ACS Chem. Biol. 4:865-874. http://dx.doi.org/10.1021/cb900194x.
32. Völler GH, Krawczyk JM, Pesic A, Krawczyk B, Nachtigall J, Süssmuth RD. 2012. Characterization of new class III lantibiotics-erythreapeptin, avermipeptin and griseopeptin from Saccharopolyspora erythraea, Streptomyces avermitilis and Streptomyces griseus demonstrates stepwise N-terminal leader processing. Chembiochem 13:1174-1183. http://dx.doi.org/10.1002/cbic.201200118.
33. Rink R, Kuipers A, de Boef E, Leenhouts KJ, Driessen AJ, Moll GN, Kuipers OP. 2005. Lantibiotic structures as guidelines for the design of peptides that can be modified by lantibiotic enzymes. Biochemistry 44: 8873-8882. http://dx.doi.org/10.1021/bi050081h.
34. Xiong Z, Jiang Y, Qi D, Lu H, Yang F, Yang J, Chen L, Sun L, Xu X, Xue Y, Zhu Y, Jin Q. 2009. Complete genome sequence of the extremophilic Bacillus cereus strain Q1 with industrial applications. J. Bacteriol. 191: 1120-1121. http://dx.doi.org/10.1128/JB.01629-08.
35. Begley M, Cotter PD, Hill C, Ross RP. 2009. Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins. Appl. Environ. Microbiol. 75:5451-5460. http://dx.doi.org/10.1128/AEM.00730-09.
36. Lubelski J, Rink R, Khusainov R, Moll G, Kuipers O. 2008. Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. Cell. Mol. Life Sci. 65:455-476. http://dx.doi.org/10.1007/s00018-007-7171-2.
37. Meyer HE, Heber M, Eisermann B, Korte H, Metzger JW, Jung G. 1994. Sequence analysis of lantibiotics: chemical derivatization procedures allow a fast access to complete Edman degradation. Anal. Biochem. 223: 185-190. http://dx.doi.org/10.1006/abio.1994.1571.
38. van Heel AJ, de Jong A, Montalban-Lopez M, Kok J, Kuipers OP. 2013. BAGEL3: automated identification of genes encoding bacteriocins and (non-)bactericidal posttranslationally modified peptides. Nucleic Acids Res. http://dx.doi.org/10.1093/nar/gkt391.
39. Foulston LC, Bibb MJ. 2010. Microbisporicin gene cluster reveals unusual features of lantibiotic biosynthesis in actinomycetes. Proc. Natl. Acad. Sci. U. S. A. 107:13461-13466. http://dx.doi.org/10.1073/pnas.1008285107.
40. Sherwood EJ, Hesketh AR, Bibb MJ. 2013. Cloning and analysis of the planosporicin lantibiotic biosynthetic gene cluster of Planomonospora alba. J. Bacteriol. 195:2309-2321. http://dx.doi.org/10.1128/JB.02291-12.
41. Marsh AJ, O'Sullivan O, Ross RP, Cotter PD, Hill C. 2010. In silico analysis highlights the frequency and diversity of type 1 lantibiotic gene clusters in genome sequenced bacteria. BMC Genomics 11:679. http://dx.doi.org/10.1186/1471-2164-11-679.
42. Yonezawa H, Kuramitsu HK. 2005. Genetic analysis of a unique bacteriocin, Smb, produced by Streptococcus mutans GS5. Antimicrob. Agents Chemother. 49:541-548. http://dx.doi.org/10.1128/AAC.49.2.541-548.2005.
43. Day A, Cove J, Phillips-Jones M. 2003. Cytolysin gene expression in Enterococcus faecalis is regulated in response to aerobiosis conditions. Mol. Genet. Genomics 269:31-39. http://dx.doi.org/10.1007/s00438-003-0819-1.
44. Caetano T, Krawczyk JM, Mösker E, Süssmuth RD, Mendo S. 2011. Heterologous expression, biosynthesis, and mutagenesis of type II lantibiotics from Bacillus licheniformis in Escherichia coli. Chem. Biol. 18:90-100. http://dx.doi.org/10.1016/j.chembiol.2010.11.010.
45. Booth MC, Bogie CP, Sahl HG, Siezen RJ, Hatter KL, Gilmore MS. 1996. Structural analysis and proteolytic activation of Enterococcus faecalis cytolysin, a novel lantibiotic. Mol. Microbiol. 21:1175-1184. http://dx.doi.org/10.1046/j.1365-2958.1996.831449.x.
46. Furgerson Ihnken L, Chatterjee C, van der Donk WA. 2008. In vitro reconstitution and substrate specificity of a lantibiotic protease. Biochemistry 47:7352-7363. http://dx.doi.org/10.1021/bi800278n.
47. Lin Y, Teng K, Huan L, Zhong J. 2011. Dissection of the bridging pattern of bovicin HJ50, a lantibiotic containing a characteristic disulfide bridge. Microbiol. Res. 166:146-154. http://dx.doi.org/10.1016/j.micres.2010.05.001.
48. Tang W, van der Donk WA. 2012. Structural characterization of four prochlorosins: a novel class of lantipeptides produced by planktonic marine cyanobacteria. Biochemistry 51:4271-4279. http://dx.doi.org/10.1021/bi300255s.
49. Kodani S, Hudson ME, Durrant MC, Buttner MJ, Nodwell JR, Willey JM. 2004. The SapB morphogen is a lantibiotic-like peptide derived from the product of the developmental gene ramS in Streptomyces coelicolor. Proc. Natl. Acad. Sci. U. S. A. 101:11448-11453. http://dx.doi.org/10.1073/pnas.0404220101.
50. Skaugen M, Nissen-Meyer J, Jung G, StevanoVic S, Sletten K, Inger C, Abildgaard M, Nes I. 1994. In vivo conversion of L-serine to D-alanine in a ribosomally synthesized polypeptide. J. Biol. Chem. 269:27183-27185.
51. Tang W, van der Donk WA. 2013. The sequence of the enterococcal cytolysin imparts unusual lanthionine stereochemistry. Nat. Chem. Biol. 9:157-159. http://dx.doi.org/10.1038/nchembio.1162.
52. Haas W, Gilmore MS. 1999. Molecular nature of a novel bacterial toxin: the cytolysin of Enterococcus faecalis. Med. Microbiol. Immunol. 187:183-190. http://dx.doi.org/10.1007/s004300050091.
53. Knerr PJ, van der Donk WA. 2013. Chemical synthesis of the lantibiotic lacticin 481 reveals the importance of lanthionine stereochemistry. J. Am. Chem. Soc. 135:7094-7097. http://dx.doi.org/10.1021/ja4014024.